Get started
Author

Claudio Iannacone

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
2012 · Vincent Rijckborst, Bettina E. Hansen, et al. · Journal of Hepatology · 170
Prevalence of fatigue in Parkinson disease and its clinical correlates
2014 · Fabrizio Stocchi, Giovanni Abbruzzese, et al. · Neurology · 137
Long‐term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open‐label, cohort study
2014 · Laura Gragnani, Elisa Fognani, et al. · Hepatology · 131
PDF
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
2012 · Pietro Lampertico, Mauro Viganò, et al. · Gut · 117
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
2014 · R. Buzzoni, S. Pusceddu, et al. · Annals of Oncology · 69
PDF
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
2014 · Cesare Gridelli, Silvia Novello, et al. · Journal of Thoracic Oncology · 30
PDF
Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update
2017 · Emilio Bajetta, Laura Catena, et al. · Neuroendocrinology · 22
98 Extended (2 Years) Treatment With Peginterferon Alfa-2a [40kd] Improves Sustained Response Rates in Genotype D Patients With Hbeag Negative Chronic Hepatitis B
2010 · P. Lampertico, M. Vigano, et al. · Journal of Hepatology · 21
PDF
780 Predictors of Svr in Naive Hcv G1 Patients in Real Life Practice: the Probe
2008 · A. Craxi, F. Piccinino, et al. · Journal of Hepatology · 16
PDF
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial
2023 · Stefania Capone, Francesco M. Fusco, et al. · Cell Reports Medicine · 13
PDF
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study
2018 · Milvia Zambetti, Filippo Montemurro, et al. · European Journal of Cancer · 13
Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial
2022 · Silvia Bonanno, Riccardo Giossi, et al. · Journal of Neurology · 12
PDF
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
2016 · Silvio Danese, Ailsa Hart, et al. · BMJ Open Gastroenterology · 12
PDF
829 Effectiveness of Hepatitis C Virus Treatment in Real-life Practice: a Prospective Observational Multicenter Study in Italy (probe)
2008 · M. Rizzetto, M. Colombo, et al. · Journal of Hepatology · 9
Cytopenias during Treatment of HIV–HCV-Coinfection with Pegylated Interferon and Ribavirin: Safety Analysis of the OPERA Study
2014 · Emanuele Pontali, Elena Angeli, et al. · Antiviral Therapy · 8
Dexamethasone/Netilmicin Eye Drops and Eye Gel for the Treatment of Ocular Inflammation After Micro-Incisional Vitreoretinal Surgery
2020 · Antonio Rapisarda, Paolo Arpa, et al. · Clinical ophthalmology · 7
PDF
Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV–HIV Coinfection in Interferon-Naive Patients
2013 · Giampiero Carosi, Raffaele Bruno, et al. · Antiviral Therapy · 7
730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS
2011 · P. Lampertico, M. Viganò, et al. · Journal of Hepatology · 5
PDF
OPERA : responses to peginterferon and ribavirin therapy in a subgroup of interferon‐naïve patients with HIV / HCV genotype 2/3 co‐infection in Italy
2014 · Raffaele Bruno, Giuseppe Cariti, et al. · Liver International · 4
Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714).
2012 · Cesare Gridelli, Silvia Novello, et al. · Journal of Clinical Oncology · 4
Real-world outcomes in patients with chronic hepatitis C
2014 · Antonio Craxì, Felice Piccinino, et al. · European Journal of Gastroenterology & Hepatology · 3
O.064 Antiviral treatment for hepatitis C virus infection in the real practice: A nationwide Italian experience (the PROBE study)
2006 · A. Alberti, A. Ascione, et al. · Journal of Clinical Virology · 2
Clinical Efficacy and Safety of Dexamethasone/Netilmicin Gel in the Management of Ocular Inflammation After Vitreoretinal Surgery
2013 · Vincenzo Papa, Daria Rasà, et al. · Investigative Ophthalmology & Visual Science · 1
1085 Peg-interferon and Ribavirin in Hcv-related Cirrhotic Patients With Profound Thrombocytopenia
2012 · A. Andriulli, A. Iacobellis, et al. · Journal of Hepatology · 1
Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40kd] in genotype D patients with HBeAg-negative chronic hepatitis B
2010 · Pietro Lampertico, Mauro Viganò, et al. · 1
Works count: 34
Citation count: 816
H-index: 12
I10-index: 13
Year
Topic
Type